EPA Announces Release of IRIS Toxicological Reviews for PFHxA and PFDA

EPA has announced the release of Integrated Risk Information System (IRIS)Toxicological Reviews for two PFAS compounds, perfluorohexanoic acid (PFHxA) and perfluorodecanoic acid (PFDA). These are two of the five PFAS assessments the IRIS Program is developing. The assessment for Perfluorobutanoic Acid (PFBA) was finalized in December 2022. The other two assessments for Perfluorohexanesulfonic Acid (PFHxS) and perfluorononanoic acid (PFNA) – two of the PFAS in the recently proposed National Primary Drinking Water Regulation Rulemaking (NPDWR) – are still in development.

PFHxA: EPA released the Final Report for the IRIS Toxicological Review of PFHxA and Related Salts, along with the interagency comments on the IRIS Interagency Science Discussion Draft. This assessment addresses the potential cancer and noncancer human health effects from exposure. Exposure is possible via inhalation of indoor or outdoor air, ingestion of drinking water and food, and dermal contact with PFHxA-containing products. EPA may use this assessment to inform decisions to protect human health. For more information, visit EPA’s website.

PFDA: EPA released the Public Comment and External Review Draft of the IRIS Toxicological Review of PFDA and Related Salts for a 60-day public comment period and external peer review. Exposure to PFDA is possible via inhalation of indoor or outdoor air, ingestion of drinking water and food, and dermal contact with PFDA-containing products. The deadline for comments is June 9, 2023. For more information the assessment and peer review meeting, visit EPA’s website.